Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

No new safety findings were observed in the OLE with continued lecanemab treatment over four years. Rates of amyloid-related imaging abnormalities (ARIA) decreased after the initial 12 months and ...

There’s progress in the battle against Alzheimer’s and, while there’s still no cure, new tests and treatments are presenting ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

The drug is called Leqembi, and it removes plaques in the brain that are associated with Alzheimer's. After about 18 months, ...

Medicare coverage is crucial for most patients to have any hope of being able to afford Leqembi. Eisai has priced Leqembi at $26,500 per year before insurance coverage, which is extraordinarily ...